LKFT vs ZLAB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LKFT · Lakefront Biotherapeutics$33.31 ▼ 0.24%
ZLAB · Zai Lab$21.03 ▼ 4.06%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LKFT +7.3%
- ZLAB +5.5%
Head to head
| Metric | LKFT | ZLAB |
|---|---|---|
| Price | $33.31 | $21.03 |
| Change today | ▼ 0.24% | ▼ 4.06% |
| Market cap | $2.18B | $2.36B |
| Return, 3 months | +14.7% | -18.0% |
| Return, year to date | +1.9% | +19.2% |
| Return, 1 year | +8.6% | +5.0% |
| P/E (TTM) | 2.5 | – |
| P/B | 0.6 | 4.2 |
| P/E percentile vs own 5y | 61st | 15th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -89.4% | -6.8% |
| Net profit growth (YoY) | +98.7% | -28.3% |
| Gross margin | 98.1% | 54.7% |
| Operating margin | 65.8% | -61.7% |
| Net margin | 85.9% | -44.9% |
| Return on equity | 28.0% | -30.0% |
| Analyst target vs. price | +35.1% | +87.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 57 | 37 |
| 30-day volatility | 25.7% | 72.3% |
| Max drawdown, 1 year | -24.7% | -34.7% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZLAB is the largest of the group by market value.
- LKFT has returned the most over the past year.
- ZLAB is growing revenue fastest.
- LKFT keeps the most profit per dollar of sales.
- LKFT has been the calmest stock over the last 30 days.